Reviewer's report
Title:Association of MRC-1 and IL-28B with the treatment outcome of hepatitis
C: a case control study
Version: 1Date:10 October 2013
Reviewer: Salvatore Petta
Reviewer's report:
In this study PENG and colleagues tested in a Chinese population the
performance of IL28B and MRC-1 SNP in the prediction of both RVR and SVR to
PEG-IFN plus RBV therapy. The overall interest of the is limited by different
issues:
1) In an era where PEG-IFN plus RBV therapy is not more the standard therapy
for CHC, due to the actual availability of first generation PIs, and the next
availability of new shorter therapeutic regimens with or without IFN, this study
does not add clinical relevant data. In fact this study falls to identify, in addition to
the well known role of IL28B, a very effective prediction rule for selection of
patients for PEG-IFN/RBV only
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
none
Reviewer's report
Title:Association of MRC-1 and IL-28B with the treatment outcome of hepatitis
C: a case control study
Version: 1Date:10 October 2013
Reviewer: Salvatore Petta
Reviewer's report:
In this study PENG and colleagues tested in a Chinese population the
performance of IL28B and MRC-1 SNP in the prediction of both RVR and SVR to
PEG-IFN plus RBV therapy. The overall interest of the is limited by different
issues:
1) In an era where PEG-IFN plus RBV therapy is not more the standard therapy
for CHC, due to the actual availability of first generation PIs, and the next
availability of new shorter therapeutic regimens with or without IFN, this study
does not add clinical relevant data. In fact this study falls to identify, in addition to
the well known role of IL28B, a very effective prediction rule for selection of
patients for PEG-IFN/RBV only
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
none
Please review this paper.
user
Reviewer's report
Title:Association of MRC-1 and IL-28B with the treatment outcome of hepatitis
C: a case control study
Version: 1Date:10 October 2013
Reviewer: Salvatore Petta
Reviewer's report:
In this study PENG and colleagues tested in a Chinese population the
performance of IL28B and MRC-1 SNP in the prediction of both RVR and SVR to
PEG-IFN plus RBV therapy. The overall interest of the is limited by different
issues:
1) In an era where PEG-IFN plus RBV therapy is not more the standard therapy
for CHC, due to the actual availability of first generation PIs, and the next
availability of new shorter therapeutic regimens with or without IFN, this study
does not add clinical relevant data. In fact this study falls to identify, in addition to
the well known role of IL28B, a very effective prediction rule for selection of
patients for PEG-IFN/RBV only
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
none
assistant